Progress in the development of biochemical and neuroimaging biomarkers of AD

( identify individuals on the AD trajectory )

Please Help Support Alzheimer's Research Today! 
Your Alzheimer's donation will help billions live without it.
DONATE NOW

On the 9 June 2010, 119 participants from industry, academia, and related stakeholder communities in the U.S. and Europe joined Alzforum for a Webinar, "Treating Before Symptoms-ADCS Invites Ideas for Clinical Trials in Very Early AD," presented by Alzheimer's Disease Cooperative Study (ADCS) director Paul Aisen, MD. In the webinar, Dr. Aisen explained what kinds of project ideas the ADCS leaders welcome from the worldwide Alzheimer Disease research community as they prepare for a new round of federal ADCS funding next year. The ADCS runs trials with public-private collaborations, and has developed a clinical trial infrastructure and a tool kit well suited to push drug trials into the pre-symptomatic phase of the disease. Joining Aisen for a panel discussion were these notable leaders: Reisa Sperling, BWH; Lon Schneider, USC; Randy Bateman, WashU; Maria Carrillo, Alzheimer's Association, Eric Siemers, Lilly; Pablo Lapuerta and Howard Feldman, BMS; and Dana Hilt, EnVivo Pharmaceuticals.

In his introductory text posted on the Alzforum webinar page, Dr. Aisen writes: "In recent decades, dramatic strides in elucidating the biochemical and cellular mechanisms underlying Alzheimer disease (AD) have led to general optimism that effective disease-modifying interventions may be within reach. Plausible targets have yielded treatments that have advanced into efficacy trials. But the results of those trials have been painfully disappointing. One pivotal trial after another has failed to demonstrate favorable effects on cognitive and clinical measures; xaliproden, tarenflurbil, tramiprosate, rosiglitazone, and most recently, Dimebon have all failed to achieve their primary endpoints in Phase 3 trials. No new treatment has reached the clinic since approval of the last symptomatic medication, memantine, in 2003. Read more:  medilexicon.com

TODAY'S PHOTO

   

Apple juice improves behavior but not cognition in Alzheimer's patients

Apple juice can be a useful supplement for calming the declining moods that are part of the normal progression of moderate-to-severe Alzheimer's Disease (AD), according to a study in American Journal of Alzheimer's Disease and Other Dementias (AJADD), published by SAGE. Read more: physorg.com

Беларусь ТВ

Posted YVN (AMYLOID @ PHOTO)